SEC Form 4 · accession 0001179110-17-010601
Kala Pharmaceuticals, Inc. · KALA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark T Iwicki
Officer — Chief Executive Officer · Director · 10% Owner
Period of report
Jul 19, 2017
Accepted (ET)
Jul 21, 2017 · 4:22 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479419
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $15.00 | Jul 19, 2017 | A | 78,632 | A | — | Jul 18, 2027 | Common Stock | 78,632 | 78,632 | D |
Explanation of responses
- F1This option was granted, effective on July 19, 2017 and vests over four years, with 2.0833% of the shares underlying the option vesting on August 31, 2017 and an additional 2.0833% of the shares vesting at the end of each successive one-month period thereafter.